达普司他治疗非透析患者贫血
这项随机、开放标签、心血管结局盲法裁决的3期试验比较了达普司他与达依泊汀α治疗非透析慢性肾脏病贫血,共纳入3872例患者。主要终点为基线至第28–52周血红蛋白平均变化及首次主要不良心血管事件(MACE)。达普司他组血红蛋白变化为0.74±0.02 g/dl,达依泊汀α组为0.66±0.02 g/dl,差异0.08 g/dl(95%CI 0.03–0.13),达到预设非劣效界值-0.75 g/dl。中位随访1.9年,MACE发生率两组分别为19.5%与19.2%(HR 1.03,95%CI 0.89–1.19),达到预设非劣效界值1.25。两组不良事件发生率相似。
要点
- 非透析CKD贫血患者中,达普司他组血红蛋白变化0.74±0.02 g/dl vs 达依泊汀α组0.66±0.02 g/dl,差异0.08 g/dl(95%CI 0.03–0.13),达到非劣效界值-0.75 g/dl。
- 中位随访1.9年,达普司他组MACE发生378/1937例(19.5%),达依泊汀α组371/1935例(19.2%),HR 1.03(95%CI 0.89–1.19),达到非劣效界值1.25。
- 两组不良事件发生率相似。
- 该研究为随机、开放标签、3期试验,心血管结局采用盲法裁决。
- 研究纳入非透析慢性肾脏病贫血患者,共3872例随机分组。
适用人群与场景
- 非透析慢性肾脏病贫血患者,共3872例随机分组。
研究设计与关键结果
- 研究设计:随机、开放标签、3期试验,心血管结局盲法裁决,比较达普司他与达依泊汀α治疗非透析慢性肾脏病贫血,共3872例患者随机分组。
- 主要终点1:基线至第28–52周血红蛋白平均变化,达普司他组0.74±0.02 g/dl vs 达依泊汀α组0.66±0.02 g/dl,差异0.08 g/dl(95%CI 0.03–0.13),达到预设非劣效界值-0.75 g/dl。
- 主要终点2:中位随访1.9年,首次MACE(全因死亡、非致死性心肌梗死或非致死性卒中的复合终点)达普司他组378/1937例(19.5%)vs 达依泊汀α组371/1935例(19.2%),HR 1.03(95%CI 0.89–1.19),达到预设非劣效界值1.25。
- 不良事件:两组不良事件发生率相似。
证据类型、等级与局限
- 证据类型:随机、开放标签、3期试验,心血管结局盲法裁决。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在非透析慢性肾脏病贫血患者中,达普司他在血红蛋白变化和心血管结局方面不劣于达依泊汀α。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. In patients with chronic kidney disease (CKD) who are not undergoing dialysis, the efficacy and safety of daprodustat, as compared with the conventional erythropoiesis-stimulating agent darbepoetin alfa, are unknown.
METHODS: In this randomized, open-label, phase 3 trial with blinded adjudication of cardiovascular outcomes, we compared daprodustat with darbepoetin alfa for the treatment of anemia in patients with CKD who were not undergoing dialysis. The primary outcomes were the mean change in the hemoglobin level from baseline to weeks 28 through 52 and the first occurrence of a major adverse cardiovascular event (MACE; a composite of death from any cause, nonfatal myocardial infarction, or nonfatal stroke).
RESULTS: Overall, 3872 patients were randomly assigned to receive daprodustat or darbepoetin alfa. The mean (±SD) baseline hemoglobin levels were similar in the two groups. The mean (±SE) change in the hemoglobin level from baseline to weeks 28 through 52 was 0.74±0.02 g per deciliter in the daprodustat group and 0.66±0.02 g per deciliter in the darbepoetin alfa group (difference, 0.08 g per deciliter; 95% confidence interval [CI], 0.03 to 0.13), which met the prespecified noninferiority margin of -0.75 g per deciliter. During a median follow-up of 1.9 years, a first MACE occurred in 378 of 1937 patients (19.5%) in the daprodustat group and in 371 of 1935 patients (19.2%) in the darbepoetin alfa group (hazard ratio, 1.03; 95% CI, 0.89 to 1.19), which met the prespecified noninferiority margin of 1.25. The percentages of patients with adverse events were similar in the two groups.
CONCLUSIONS: Among patients with CKD and anemia who were not undergoing dialysis, daprodustat was noninferior to darbepoetin alfa with respect to the change in the hemoglobin level from baseline and with respect to cardiovascular outcomes. (Funded by GlaxoSmithKline; ASCEND-ND ClinicalTrials.gov number, NCT02876835.).
参考来源
- Singh AK, Carroll K, McMurray JJV, et al. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021. PMID: 34739196. doi:10.1056/NEJMoa2113380
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。